First Volunteer Dosed in Innocare’s New VAV1 Degrader Trial
InnoCare has dosed the first healthy volunteer in China with ICP-538, an oral VAV1-directed molecular glue degrader. It is...
First Patient Dosed in Bioversys’ Phase 2b ALPE TB Trial
In earlier clinical work, the alpibectir–ethionamide combination (AlpE) delivered a 7‑day early bactericidal activity signal comparable to isoniazid and...
BBP-418 Shows Efficacy, Safety in Phase 3 LGMD2I/R9 Study
BridgeBio’s BBP-418 delivered functional and biomarker gains in the Phase 3 FORTIFY interim analysis for LGMD2I/R9: at 12 months,...
Solid Biosciences Duchenne Trial Sees Positive Interim Update
In updated interim data from the Phase 1/2 INSPIRE DUCHENNE study, 40 participants have received SGT-003 to date. Among...
Injectable Buprenorphine Lowers OUD Healthcare Costs, Study
Patients adherent to the monthly extended-release buprenorphine injection for 12 months posted 42% lower adjusted non-MOUD medical costs compared...
Breakthrough Diabetes Study: Positive Results Past One Year
At 14 months post-transplant, a single patient in an investigator-sponsored study maintained detectable fasting and meal-stimulated C-peptide, with mixed-meal...
Vima’s Hope: First Dystonia Patient Dosed in Phase 2 Study
Phase 1 data for VIM0423 showed the oral agent was safe and well tolerated through 28 days in healthy...
Sellas Launches Pioneering AML Trial, Enrolls First Patient
SELLAS’ CDK9 inhibitor SLS009 (tambiciclib) previously delivered a 33% overall response rate across evaluable relapsed/refractory AML patients, rising to...
Aplagon Announces Dosing in Phase 2a Ischemia Trial
Aplagon has dosed the first patient in HEALING, a Phase 2a study of APAC in chronic limb-threatening ischemia secondary...
c-bio Cleared for T-Cell Therapy Trial in Cervical Cancer
Cbio has received regulatory clearance to initiate a first‑in‑human Phase I/IIa study of novoleucel in persistent or recurrent cervical...